Insider Selling: EXACT Sciences Co. (EXAS) SVP Sells 1,665 Shares of Stock

EXACT Sciences Co. (NASDAQ:EXAS) SVP D Scott Coward sold 1,665 shares of EXACT Sciences stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $52.54, for a total transaction of $87,479.10. Following the sale, the senior vice president now owns 37,558 shares in the company, valued at $1,973,297.32. The sale was disclosed in a document filed with the SEC, which is available through this link.

Shares of EXACT Sciences Co. (NASDAQ:EXAS) traded up $0.31 during trading on Thursday, reaching $56.14. 1,275,991 shares of the company’s stock traded hands, compared to its average volume of 1,780,367. The stock has a market cap of $6,720.00, a P/E ratio of -48.82 and a beta of 0.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98. EXACT Sciences Co. has a 52 week low of $14.60 and a 52 week high of $63.60.

EXACT Sciences (NASDAQ:EXAS) last issued its earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. The business had revenue of $72.60 million for the quarter, compared to the consensus estimate of $65.03 million. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. The business’s quarterly revenue was up 158.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.36) earnings per share. sell-side analysts anticipate that EXACT Sciences Co. will post -1.1 earnings per share for the current year.

Several equities research analysts recently commented on EXAS shares. Canaccord Genuity reiterated a “buy” rating and set a $45.00 price target on shares of EXACT Sciences in a research note on Thursday, September 7th. Jefferies Group lifted their price target on shares of EXACT Sciences to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Bank of America set a $56.00 price target on shares of EXACT Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. Robert W. Baird reissued a “buy” rating and set a $49.00 price objective on shares of EXACT Sciences in a research report on Friday, October 6th. Finally, Zacks Investment Research raised shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $51.00 price objective on the stock in a research report on Tuesday, September 26th. Eight analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $50.58.

Several large investors have recently modified their holdings of EXAS. Fred Alger Management Inc. purchased a new stake in shares of EXACT Sciences in the second quarter valued at about $84,177,000. Lord Abbett & CO. LLC boosted its holdings in shares of EXACT Sciences by 59.1% in the second quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after acquiring an additional 875,527 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of EXACT Sciences by 8.0% in the second quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock valued at $334,589,000 after acquiring an additional 700,051 shares in the last quarter. Green Valley Investors LLC purchased a new stake in shares of EXACT Sciences in the second quarter valued at about $20,892,000. Finally, FMR LLC boosted its holdings in shares of EXACT Sciences by 32.7% in the second quarter. FMR LLC now owns 2,318,269 shares of the medical research company’s stock valued at $81,997,000 after acquiring an additional 571,796 shares in the last quarter. 82.39% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/04/insider-selling-exact-sciences-co-exas-svp-sells-1665-shares-of-stock.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply